TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody
TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Jun 23
TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses
19 Jun 23
BAT2206 is a proposed biosimilar to Janssen’s Stelara1, which is currently approved in Brazil for the treatment of…
16 Jun 23
Camzyos is already approved in the US, to treat adults with symptomatic New York Heart Association (NYHA) class…
16 Jun 23
According to the medical technology company, the trial is expected to use F-CD8 targeted imaging radiopharmaceutical to detect…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Jun 23
Fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and…
16 Jun 23
In the study, Risankizumab achieved the primary endpoint of clinical remission at week 52 and met its key…
16 Jun 23
Since its initial listing, Viva Biotech has successfully completed mergers and acquisitions, including SYNthesis and Langhua Pharmaceutical, resulting…
16 Jun 23
The acquisition presents exciting opportunities for accelerated growth as it expands Rosemont's portfolio and grants access to new…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Jun 23
Collaboration to make use of Confo’s unique suite of ConfoBody-enabled antibody discovery technologies on two GPCR targets
16 Jun 23
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while…
PharmaceuticalsConsulting, Training and Other Pharmaceutical Services